A new CDC study found up to 30% of blood donors in some US states carry the antibody, against a national clinical diagnosis rate near 0.14%, a roughly 200 fold gap scientists cannot yet explain.
In some parts of the United States, up to 1 in 3 blood donors carry the antibody that primes the body to react to red meat. The national rate of clinically diagnosed alpha-gal syndrome, the tick-borne allergy those antibodies signal, is closer to 1 in 700. The roughly 200-fold gap between sensitization and disease is not a measurement artifact. It is a scientific mystery with direct consequences for testing and patient counseling.
A new study from the Centers for Disease Control and Prevention, published in the agency's Morbidity and Mortality Weekly Report (MMWR), tested blood samples from donors across 10 states between 2024 and 2025. In some regions, nearly 30% of samples carried IgE antibodies against alpha-gal, a sugar called galactose-α-1,3-galactose that decorates the cells of cows, pigs, and other nonprimate mammals. The CDC's prior working estimate for clinically diagnosed alpha-gal syndrome in the US population was about 0.14%, or roughly 450,000 people, as covered by Ars Technica. The new regional seroprevalence is two orders of magnitude higher than the diagnosed count, and the study authors are explicit about what that does and does not mean.
The trigger for sensitization in the US is usually the lone star tick, Amblyomma americanum, whose saliva contains alpha-gal. A bite can train the immune system to treat the sugar as a threat, so the next hamburger or pork chop can trigger an allergic reaction hours later. Symptoms show up two to six hours after a meal. That delay is why a midnight bout of hives, vomiting, or anaphylaxis rarely gets traced back to the steak eaten at dinner.
That delay is part of why so few cases get caught. A person who eats red meat and wakes up at 2 a.m. with throat tightening and dizziness rarely connects the symptoms to the steak, and many clinicians do not either. Alpha-gal syndrome was only formally described in the medical literature in the early 2000s, and there is still no widely used in-office diagnostic test. The current clinical standard, a suggestive history plus a positive blood antibody result plus improvement on a diet that excludes mammalian products, requires the patient and the doctor to suspect it in the first place.
The MMWR study does not change that diagnostic gap, and the authors are careful not to. They describe the regional seroprevalence as high and call for more research to understand what turns a sensitized person into a symptomatic one. They also flag the possibility that diagnostic difficulty is itself inflating the undercount, a point other allergists have made for years. If a disease is hard to recognize, the diagnosed fraction will look small even if real disease is more common. The new numbers do not settle that question. They sharpen it.
The other moving piece is geography. Lone star tick range has been expanding northward and westward for at least two decades, carried in part by white-tailed deer populations and warming winters. As the tick moves, sensitization is likely to follow. The MMWR study deliberately sampled states with known lone star activity, so the regional results should not be read as a national average. They are a signal about what sensitization can look like where the vector is established, and a preview of what neighboring states may see next.
Tick-bite prevention works: permethrin-treated clothing, DEET-based repellents, and prompt tick checks after time in wooded or grassy areas reduce the chance of sensitization in the first place. Anyone who has had unexplained hives, stomach upset, or dizziness two to six hours after eating red meat, pork, or gelatin, or after drinking milk, should ask a clinician about alpha-gal testing rather than trying to self-diagnose. Severe symptoms, including trouble breathing, throat tightening, swelling of the tongue or lips, dizziness, weak pulse, or a drop in blood pressure, are anaphylaxis and need emergency care.
What the MMWR data do not yet tell us is which of the roughly 1 in 3 sensitized people in high-prevalence regions, if any, will eventually join the much smaller group whose next steak sends them to the hospital. Until that piece of the puzzle is solved, the antibody is a warning sign with no reliable forecast attached.